Brain metastasis from follicular thyroid carcinoma: Treatment with sorafenib

Thyroid

Volumn 22, Issue 8, 2012, Pages 856-860

  Shen, Yan ^a,b   Ruan, Maomei ^a,b   Luo, Quanyong ^a   Yu, Yongli ^a   Lu, Hankui ^a   Zhu, Ruisen ^a   Chen, Libo ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; SORAFENIB;

ADULT; ALOPECIA; BRAIN DAMAGE; BRAIN METASTASIS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIZZINESS; DRUG EFFECT; DYSPNEA; FEMALE; FOLLICULAR CARCINOMA; HEADACHE; HEMIPLEGIA; HUMAN; LOW DRUG DOSE; LUNG METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PARIETAL LOBE; PRIORITY JOURNAL; RADIOGRAPHY; RADIOSURGERY; REVIEW; THYROID CARCINOMA; THYROIDECTOMY; VOMITING;

ADENOCARCINOMA, FOLLICULAR; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; BRAIN NEOPLASMS; FEMALE; HUMANS; IODINE RADIOISOTOPES; LUNG NEOPLASMS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PYRIDINES; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 84864668516     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2011.0419     Document Type: Review

References (16)

1. Dinneen SF, Valimaki MJ, Bergstralh EJ, Goellner JR, Gorman CA, Hay ID 1995 Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades. J Clin Endocrinol Metab 80:2041-2045.
2. Chiu AC, Delpassand ES, Sherman SI 1997 Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab 82:3637-3642.
3. Fujita T, Ogasawara Y, Doihara H 2009 Solitary cranial metastasis of thyroid carcinoma 13 years after primary surgery: Report of a case. Surg Today 39:44-47.
4. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM; American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214.
5. Deshpande HA, Gettinger SN, Sosa JA 2008 Novel chemotherapy options for advanced thyroid tumors: Small molecules offer great hope. Curr Opin Oncol 20:19-24.
6. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA 2004 BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109.
7. Chen L, Shen Y, Luo Q, Yu Y, Lu H, Zhu R 2011 Response to sorafenib at a low dose in patients with radioiodinerefractory pulmonary metastases from papillary thyroid carcinoma. Thyroid 21:119-124.
8. Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, Lopez A, Sherman SI, Busaidy NL 2010 Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: The M.D. Anderson experience. J Clin Endocrinol Metab 95:2588-2595.
9. Krajewska J, Olczyk T, Roskosz J, Paliczk-Cieślik E, Smietana AK, Kaczmarek-Borowska B, Jarza̧b B 2010 Treatment with sorafenib in advanced thyroid cancer-a case report. Endokrynol Pol 61:492-496.
10. Aschebrook-Kilfoy B, Ward MH, Sabra MM, Devesa SS 2011 Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006. Thyroid 21:125-134.
11. Kobayashi T, Asakawa H, Komoike Y, Tamaki Y, Monden M 1999 Characteristics and prognostic factors in patients with differentiated thyroid cancer who underwent a total or subtotal thyroidectomy: Surgical approach for high-risk patients. Surg Today 29:200-203.
12. McConahey WM, Hay ID, Woolner LB, van Heerden JA, Taylor WF 1986 Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: Initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc 61:978-996.
13. McWilliams RR, Giannini C, Hay ID, Atkinson JL, Stafford SL, Buckner JC 2003 Management of brain metastases from thyroid carcinoma: A study of 16 pathologically confirmed cases over 25 years. Cancer 98:356-362.
14. Haugen BR, Kane MA 2010 Approach to the thyroid cancer patient with extracervical metastases. J Clin Endocrinol Metab 95:987-993.
15. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS 2008 Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714-4719.
16. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE Jr, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH 2009 Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27:1675-1684.